DiaMedica Therapeutics: Stroke Developer With Low Cash Reserve

2025-04-15 20:54:24 ET

Summary

• DiaMedica Therapeutics is developing DM199 for acute ischemic stroke and preeclampsia, with promising AIS clinical trial progress and Fast Track Designation by the FDA.
• DM199 aims to extend the treatment window for AIS to 24 hours, potentially benefiting 90% of patients versus the current 20% within 4.5 hours.
• The AIS ReMEDy2 trial is an adaptive, double-blind, placebo-controlled study, with completion anticipated in December 2026 and an interim analysis after 200 participants.
• With a modest cash runway into Q3 2026, DMAC faces significant competition and limited near-term catalysts, making it a high-risk speculative hold.

This is my first DiaMedica Therapeutics ( DMAC ) article. DiaMedica is a clinical stage biopharmaceutical company with one primary product in clinical development for two indications. These are:

1. DM199 in a Pivotal Phase 2/3 trial for the treatment of acute ischemic stroke [AIS] and
2. DM199 in a Phase 2 trial for Preeclampsia.

Read the full article on Seeking Alpha

For further details see: